NOTICE -- Login operations are currently offline due to an unscheduled disruption. We are waiting for LDAP services to be re-instated. We apologize for the inconvenience - June 24, 2021
W. Rathmell
Last active: 4/27/2021

  1. VHL Type 2B gene mutation moderates HIF dosage in vitro and in vivo. Lee CM, Hickey MM, Sanford CA, McGuire CG, Cowey CL, Simon MC, Rathmell WK (2009) Oncogene 28(14): 1694-705
    › Primary publication · 19252526 (PubMed) · PMC2667565 (PubMed Central)
  2. VHL gene mutations in renal cell carcinoma: role as a biomarker of disease outcome and drug efficacy. Cowey CL, Rathmell WK (2009) Curr Oncol Rep 11(2): 94-101
    › Primary publication · 19216840 (PubMed) · PMC2873025 (PubMed Central)
  3. Ror2, a developmentally regulated kinase, promotes tumor growth potential in renal cell carcinoma. Wright TM, Brannon AR, Gordan JD, Mikels AJ, Mitchell C, Chen S, Espinosa I, van de Rijn M, Pruthi R, Wallen E, Edwards L, Nusse R, Rathmell WK (2009) Oncogene 28(27): 2513-23
    › Primary publication · 19448672 (PubMed) · PMC2771692 (PubMed Central)
  4. Epstein-Barr virus latent membrane protein 1 is not associated with vessel density nor with hypoxia inducible factor 1 alpha expression in nasopharyngeal carcinoma tissue. Benders AA, Tang W, Middeldorp JM, Greijer AE, Thorne LB, Funkhouser WK, Rathmell WK, Gulley ML (2009) Head Neck Pathol 3(4): 276-82
    › Primary publication · 20596845 (PubMed) · PMC2811562 (PubMed Central)
  5. VHL type 2B mutations retain VBC complex form and function. Hacker KE, Lee CM, Rathmell WK (2008) PLoS One 3(11): e3801
    › Primary publication · 19030229 (PubMed) · PMC2583047 (PubMed Central)
  6. VHL inactivation in renal cell carcinoma: implications for diagnosis, prognosis and treatment. Rathmell WK, Chen S (2008) Expert Rev Anticancer Ther 8(1): 63-73
    › Primary publication · 18095884 (PubMed) · PMC2873028 (PubMed Central)
  7. Using Molecular Biology to Develop Drugs for Renal Cell Carcinoma. Cowey CL, Rathmell WK (2008) Expert Opin Drug Discov 3(3): 311-327
    › Primary publication · 20648240 (PubMed) · PMC2906134 (PubMed Central)
  8. Renal cell carcinoma. Rini BI, Rathmell WK, Godley P (2008) Curr Opin Oncol 20(3): 300-6
    › Primary publication · 18391630 (PubMed)
  9. Preoperative tyrosine kinase inhibition as an adjunct to debulking nephrectomy. Amin C, Wallen E, Pruthi RS, Calvo BF, Godley PA, Rathmell WK (2008) Urology 72(4): 864-8
    › Primary publication · 18684493 (PubMed)
  10. High-dose-intensity MVAC for Advanced Renal Medullary Carcinoma: Report of Three Cases and Literature Review. Rathmell WK, Monk JP (2008) Urology 72(3): 659-63
    › Primary publication · 18649931 (PubMed)